Piroxicam
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Piroxicam
- Pharmacist Assessment Report
- Piroxicam: Colobomatous microphthalmia-rhizomelic dysplasia syndrome
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- Australia Market Information
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Piroxicam: Colobomatous microphthalmia-rhizomelic dysplasia syndrome
One-Sentence Summary
Piroxicam is a non-steroidal anti-inflammatory drug (NSAID) originally used to treat rheumatoid arthritis and osteoarthritis. The TxGNN model’s top-ranked prediction is colobomatous microphthalmia-rhizomelic dysplasia syndrome, but this has no credible mechanistic link and no supporting studies. The most clinically plausible prediction in the data compiled for this report is juvenile idiopathic arthritis (JIA), which has 0 clinical trials and 10 publications (including 2 small piroxicam-specific paediatric comparisons from the 1980s).
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Colobomatous microphthalmia-rhizomelic dysplasia syndrome |
| TxGNN Prediction Score | 1.0000 |
| Evidence Level | L5 (rank 1); L3 (JIA) |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
| Recommended Decision | Hold (rank 1); Proceed with Guardrails limited to JIA as a research question |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Based on known information, piroxicam is a non-selective COX-1/COX-2 inhibitor. It reduces prostaglandin-mediated inflammation and pain, which underpins its use in rheumatoid arthritis and osteoarthritis.
Top-ranked predictions (ranks 1–8). The highest-scoring predictions are mostly rare genetic skeletal, limb or developmental syndromes (for example brachydactyly-syndactyly syndrome, acromesomelic dysplasia Hunter-Thompson type, brachyolmia, pseudoachondroplasia) plus WHIM syndrome. A COX inhibitor cannot correct these developmental or genetic defects. The high scores come from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, such as shared skeletal or connective tissue features, not biological evidence and not a therapeutic rationale. At most, an NSAID might give symptomatic joint pain relief in some of these conditions. No trials or literature were found for any of them.
Rheumatoid nodulosis (rank 9). This is related to rheumatoid arthritis, so symptomatic NSAID effects are conceivable. However, it is a distinct nodule-forming condition and no efficacy evidence was found.
Juvenile idiopathic arthritis (rank 10). This has the strongest rationale. JIA is an inflammatory arthritis for which NSAIDs are an established symptomatic therapy. Piroxicam-specific paediatric data exist, but they are old and concern symptom control rather than disease modification. Piroxicam is not a first-line JIA therapy in current practice, which favours disease-modifying antirheumatic drugs (DMARDs) and biologics.
Clinical Trial Evidence
Currently no related clinical trials registered (no ClinicalTrials.gov, ANZCTR or ICTRP entries were found for any predicted indication).
Literature Evidence
The following is for juvenile idiopathic arthritis (rank 10). No literature was found for the other nine predicted indications.
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 38680254 | 2024 | Systematic review / network meta-analysis | World J Clin Cases | Compares different NSAIDs for JIA; the optimal NSAID approach has not been established |
| 33632948 | 2021 | Systematic review / network meta-analysis | Indian Pediatr | Compares the efficacy and safety of nine NSAIDs in JIA |
| 2957205 | 1987 | Randomised clinical study | Eur J Rheumatol Inflamm | 26 patients (aged 3–25) randomised to piroxicam or naproxen in juvenile rheumatoid arthritis; painful and swollen joint counts decreased significantly |
| 3510686 | 1986 | Double-blind crossover study | Br J Rheumatol | Piroxicam vs naproxen in 47 children with seronegative juvenile chronic arthritis over 8 weeks; no significant difference between the two treatments reported; also discusses problems in paediatric NSAID trials |
| 1782984 | 1991 | Pharmacokinetic study | Eur J Clin Pharmacol | 10 children with rheumatoid arthritis given about 0.4 mg/kg once daily; mean half-life about 32.6 hours |
| 9890680 | 1998 | Long-term toxicity study | Clin Rheumatol | Describes long-term toxicity of antirheumatic and anti-inflammatory drugs in 117 children followed for a mean of 8.6 years |
| 2185374 | 1990 | Review | Kinderarztl Prax | Drug therapy of juvenile chronic arthritis; piroxicam is described as a newer option |
| 21175420 | 2010 | Review (indirect) | Crit Rev Ther Drug Carrier Syst | NSAID drug delivery systems in arthritis |
| 15456329 | 2004 | Review (indirect) | Drugs | Nabumetone in osteoarthritis and rheumatoid arthritis; not piroxicam-specific |
| 3539573 | 1986 | Review (indirect) | Drugs | Pirprofen review; piroxicam appears only as a comparator |
Australia Market Information
| ARTG Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| ARTG 1897W | APO-Piroxicam | Capsule 10 mg | Not available in the data compiled for this report |
Safety Considerations
Contraindications / conditions of concern (from knowledge-graph drug-disease contraindication links, not label text):
- Cardiovascular and cerebrovascular: hypertension, congestive heart failure, myocardial infarction, coronary thrombosis, stroke, cerebral infarction, thrombotic disease, cardiovascular disease
- Renal and hepatic: kidney disease, liver disease, acute liver failure, hepatitis, drug-induced liver injury, gallbladder disease
- Gastrointestinal: active peptic ulcer disease
- Haematological: blood coagulation disease, anaemia, haemoglobinopathy
- Other: substance abuse/dependence, vision disorder/blindness, pyoureter
Drug Interactions (100 interactions recorded; examples from the 20 listed):
- Moderate: acetylsalicylic acid, corticosteroids (hydrocortisone, dexamethasone, betamethasone, triamcinolone, budesonide), metformin, glimepiride, chlorpropamide, mesalazine, balsalazide, aprepitant, potassium citrate and bicarbonate, picosulfuric acid, polyethylene glycol with electrolytes
- Minor: famotidine, ranitidine, cimetidine, linaclotide
Please refer to the TGA-approved Product Information (PI) for official warnings and contraindications. The label data for this product was not available.
Conclusion and Next Steps
Decision: Hold for the top-ranked prediction (colobomatous microphthalmia-rhizomelic dysplasia syndrome) and the other predictions of ranks 2–8. Proceed with Guardrails (as a research question only) for juvenile idiopathic arthritis.
Rationale:
- The top-ranked predictions have no mechanistic link and no clinical or literature support. The high scores come from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence.
- JIA has a plausible mechanism and limited, dated piroxicam-specific paediatric data (L3). Piroxicam is not first-line in current practice, and the evidence concerns symptom control only.
To proceed, the following is needed:
- Mechanism of action data (for example from DrugBank)
- TGA Product Information with warnings, contraindications and approved indications for APO-Piroxicam
- Review of piroxicam against current JIA guidelines and alternative NSAIDs, including paediatric dosing and safety
- Cardiovascular, gastrointestinal and renal risk assessment for the target population
- Any new clinical trial registration (ANZCTR or ClinicalTrials.gov) before further development
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.